Valeant Pharmaceuticals Stock Takeover Target?
Warrior Trading | May 31, 2016 12:52AM ET
Valeant Pharmaceuticals International, Inc (NYSE:VRX)
Valeant Pharmaceuticals, the Canada based multinational specialty pharmaceutical company, has been under close scrutiny in the past several months as it has lost nearly 90% of its share price since August of 2015 on a string of negative news along with questionable business operations. In recent headlines, speculation has surfaced that VRX could stand to be a potential takeover target.
Analyst Expectations
An analyst at Piper Jaffray had the following comments on VRX.
Valeant takeover rejection report ‘difficult to fathom,’ says Piper Jaffray. Piper Jaffray analyst David Amsellem noted the report claiming that Valeant (VRX) previously rejected a takeover offer from Takeda (OTC:TKPYY) and TPG prior to appointing Joe Papa as CEO, but said he finds it “difficult to fathom” why a buyer would have interest in the entire asset portfolio, since he believes the value of its segments to be “meaningfully” below the company’s $31B in total debt outstanding. Amsellem, who thinks there would be significant strategic interest in Valeant’s gastroenterology assets, believes that any strategic activity will come in the form of asset sales or a breakup of the company. The firm keeps an Underweight rating on Valeant shares. – Thefly.com
VRX Technicals
Since August of 2015, VRX has plunged $230, or 90%. VRX was once the most valuable company in Canada until the recent collapse fueled by constant negative news on their internal business practices.
Trading just off the lows, VRX does have huge risk/reward potential as it starts to consolidate near its recent lows. Geometrically speaking, VRX has been slowly attempting to form a falling wedge pattern for several months and is nearing a completed pattern. Falling wedge patterns can resolve explosively to the upside once a proper resolution occurs. Ideally, a break of the falling wedge to the upside on high relative volume would signal a shift in momentum as the buy pressure pours in.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company focuses on eye health, dermatology and neurology therapeutic classes, primarily on branded generics, OTC products and medical devices. The Company operates through two segments: developed markets and emerging markets.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.